| [1] |
PIANTANIDA E, IPPOLITO S, GALLO D, et al. The interplay between thyroid and liver: Implications for clinical practice[J]. J Endocrinol Invest, 2020, 43(7): 885-899. DOI: 10.1007/s40618-020-01208-6. |
| [2] |
ROSS DS, BURCH HB, COOPER DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J]. Thyroid, 2016, 26(10): 1343-1421. DOI: 10.1089/thy.2016.0229. |
| [3] |
de CAMPOS MAZO DF, de VASCONCELOS GB, PEREIRA MA, et al. Clinical spectrum and therapeutic approach to hepatocellular injury in patients with hyperthyroidism[J]. Clin Exp Gastroenterol, 2013, 6: 9-17. DOI: 10.2147/CEG.S39358. |
| [4] |
ZOU H, JIN L, WANG LR, et al. Methimazole-induced cholestatic hepatitis: Two cases report and literature review[J]. Oncotarget, 2016, 7(4): 5088-5091. DOI: 10.18632/oncotarget.6144. |
| [5] |
NIKITOPOULOU E, GAZI S. Antithyroid drug induced syndrome that lies in between ANCA vasculitis and lupus-like syndrome in a 40-year-old female with Graves' disease under methimazole therapy: A case report[J]. Mediterr J Rheumatol, 2018, 29(1): 52-54. DOI: 10.31138/mjr.29.1.52. |
| [6] |
HAN R, JIANG X. Methimazole-induced insulin autoimmune syndrome in Graves' disease with hypokalemia: A case report and literature review[J]. Exp Ther Med, 2020, 20(5): 93. DOI: 10.3892/etm.2020.9221. |
| [7] |
TSAI WL, SUN WC, CHENG JS. Chronic hepatitis B with spontaneous severe acute exacerbation[J]. Int J Mol Sci, 2015, 16(12): 28126-28145. DOI: 10.3390/ijms161226087. |
| [8] |
SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific association for the study of the liver (APASL): An update[J]. Hepatol Int, 2019, 13(4): 353-390. DOI: 10.1007/s12072-019-09946-3. |
| [9] |
WIJAYA N, ONG-RAMOS C. Methimazole-induced aplastic anemia with concomitant hepatitis in a young filipina with Graves' disease[J]. J ASEAN Fed Endocr Soc, 2019, 34(1): 99-102. DOI: 10.15605/jafes.034.01.16. |
| [10] |
GOMEZ-PERALTA F, VELASCO-MARTÍNEZ P, ABREU C, et al. Hepatotoxicity in hyperthyroid patient after consecutive methimazole and propylthiouracil therapies[J]. Endocrinol Diabetes Metab Case Rep, 2018, 2018: 17-0173. DOI: 10.1530/EDM-17-0173. |
| [11] |
HEIDARI R, NIKNAHAD H, JAMSHIDZADEH A, et al. An overview on the proposed mechanisms of antithyroid drugs-induced liver injury[J]. Adv Pharm Bull, 2015, 5(1): 1-11. DOI: 10.5681/apb.2015.001. |
| [12] |
TESCHKE R, ZHU Y, JING J. Herb-induced liver injury in asia and current role of RUCAM for causality assessment in 11, 160 published cases[J]. J Clin Transl Hepatol, 2020, 8(2): 200-214. DOI: 10.14218/JCTH.2020.00009. |
| [13] |
HENNES EM, ZENIYA M, CZAJA AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology, 2008, 48(1): 169-176. DOI: 10.1002/hep.22322. |
| [14] |
|
| [15] |
KHAN AA, AHMED S, MOHAMMED A, et al. Autoimmune-like drug-induced liver injury caused by atorvastatin and demonstration of the safety profile of pravastatin: A case report and literature review[J]. Cureus, 2020, 12(3): e7299. DOI: 10.7759/cureus.7299. |
| [16] |
SUNDARAM S, VUPPALANCHI R, SAXENA R, et al. Treatment of idiosyncratic drug-induced liver injury using steroids[J]. ACG Case Rep J, 2020, 7(2): e00319. DOI: 10.14309/crj.0000000000000319. |
| [17] |
BJÖRNSSON ES, BERGMANN O, JONASSON JG, et al. Drug-induced autoimmune hepatitis: Response to corticosteroids and lack of relapse after cessation of steroids[J]. Clin Gastroenterol Hepatol, 2017, 15(10): 1635-1636. DOI: 10.1016/j.cgh.2017.05.027. |
DownLoad:
